文献速递生殖医学

hCG触发时添加FSH对IVF/ICSI结局的影响:随机双盲安慰剂对照研究

Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study.
PubMed 文献 · Hum Reprod · 2020-01-01

本研究为随机双盲安慰剂对照试验,纳入732例采用长方案GnRH激动剂行IVF/ICSI的女性,在hCG触发时分别给予尿源性FSH 450 IU或安慰剂。结果显示两组临床妊娠率分别为52.7%和51.6%,绝对率差1.1%(95%CI -6.1%至8.3%),优质胚胎率、种植率、活产率等均无显著差异,提示hCG触发时额外FSH无益。

要点

  • hCG触发时添加FSH 450 IU不改善临床妊娠率。
  • 优质胚胎率、种植率、活产率及OHSS率两组无显著差异。
  • 长方案GnRH激动剂IVF/ICSI中单用hCG触发已足够。

核心结论

  • 在长方案GnRHa的IVF/ICSI女性中,hCG触发时额外给予FSH对临床妊娠率、胚胎质量、受精率、种植率和活产率均无影响。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,单中心,2012年6月至2013年11月,共随机732例,干预组364例、安慰剂组368例,样本量计算每组需347例。

主要发现

  • 临床妊娠率安慰剂组51.6%、FSH组52.7%,绝对率差1.1%(95%CI -6.1%至8.3%)。
  • 获卵数安慰剂组10.47±4.52、FSH组10.74±5.01(P=0.44)。
  • 优质胚胎率安慰剂组37%、FSH组33.9%(P=0.093)。
  • 种植率安慰剂组35%、FSH组36%(P=0.7)。

关键数值与推荐

  • 纳入年龄≤42岁、因输卵管因素、男方因素、不明原因、子宫内膜异位症及多因素行IVF/ICSI的患者。
  • 干预组在hCG触发时给予尿源性FSH 6安瓿(450 IU),安慰剂组给予安慰剂。
  • 主要结局为临床妊娠率,次要结局包括取卵日FSH水平、获卵数、优质胚胎率、活产率和OHSS率。

临床怎么用

  • 基于本研究,长方案GnRHa的IVF/ICSI中单用hCG触发即可,无需额外添加FSH。

局限性

  • 单中心研究可能限制有效性。
  • 使用尿源性FSH而非天然FSH。
  • 未收集卵泡液以研究uFSH使用后的分子变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does an artificially induced FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? SUMMARY ANSWER: An additional FSH bolus administered at the time of hCG trigger has no effect on clinical pregnancy rate, embryo quality, fertilization rate, implantation rate and live birth rate in women undergoing the long GnRH agonist (GnRHa) protocol for IVF/ICSI. WHAT IS KNOWN ALREADY: Normal ovulation is preceded by a surge in both LH and FSH. Few randomized clinical trials have specifically investigated the role of the FSH surge. Some studies indicated that FSH given at hCG ovulation trigger boosts fertilization rate and even prevents ovarian hyperstimulation syndrome (OHSS). STUDY DESIGN, SIZE, DURATION: This was a randomized, double-blinded, placebo-controlled trial conducted at a single IVF center, from June 2012 to November 2013. A sample size calculation indicated that 347 women per group would be adequate. A total of 732 women undergoing IVF/ICSI were randomized, using electronically randomized tables, to the intervention or placebo groups. Participants and clinical doctors were blinded to the treatment allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients aged ≤42 years who were treated with IVF/ICSI owing to tubal factor, male factor, unexplained, endometriosis and multiple factors were enrolled in this trial. Subjects all received a standard long GnRHa protocol for IVF/ICSI and hCG 6000-10 000 IU to trigger oocyte maturation. A total of 364 and 368 patients were randomized to receive a urinary FSH (uFSH) bolus (6 ampules, 450 IU) and placebo, respectively, at the time of the hCG trigger. The primary outcome measure was clinical pregnancy rate. The secondary outcome measures were FSH level on the day of oocyte retrieval, number of oocytes retrieved, good-quality embryo rate, live birth rate and rate of OHSS. MAIN RESULTS AND THE ROLE OF CHANCE: There were no significant differences in the baseline demographic characteristics between the two study groups. There were also no significant differences between groups in cycle characteristics, such as the mean number of stimulation days, total gonadotrophin dose and peak estradiol. The clinical pregnancy rate was 51.6% in the placebo group and 52.7% in the FSH co-trigger group, with an absolute rate difference of 1.1% (95% CI -6.1% to 8.3%). The number of oocytes retrieved was 10.47 ± 4.52 and 10.74 ± 5.01 (P = 0.44), the rate of good-quality embryos was 37% and 33.9% (P = 0.093) and the implantation rate was 35% and 36% (P = 0.7) in the placebo group and the FSH co-trigger group, respectively. LIMITATIONS, REASONS FOR CAUTION: This was a single-center study, which may limit its effectiveness. The use of uFSH is a limitation, as this is not the same as the natural FSH. We did not collect follicular fluid for further study of molecular changes after the use of uFSH as a co-trigger. WIDER IMPLICATIONS OF THE FINDINGS: Based on previous data and our results, an additional FSH bolus administered at the time of hCG trigger has no benefit on clinical pregnancy rates in women undergoing the long GnRHa protocol in IVF/ICSI: a single hCG trigger is sufficient. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Key Research and Development Program of China (2016YFC1000205); Sun Yat-Sen University Clinical Research 5010 Program (2016004); the Science and Technology Project of Guangdong Province (2016A020216011 and 2017A020213028); and Science Technology Research Project of Guangdong Province (S2011010004662). There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: The trial was registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-12002246). TRIAL REGISTRATION DATE: 20 May 2012. DATE OF FIRST PATIENT’S ENROLMENT: 10 June 2012.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Qiu Q, Huang J, Li Y, et al. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study. Hum Reprod. 2020. PMID: 32383771. doi:10.1093/humrep/deaa087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。